June 2026: Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Dr. Jason Tucciarone and Dr. Alan Schatzberg (Stanford University, Stanford, CA) join AJP Audio to discuss the use of low-dose buprenorphine as an adjunctive therapy to extend the anti-suicidal effects of ketamine treatment in patients with major depressive disorder and suicidal ideation. AJP Editor-in-Chief Dr. Ned Kalin joins to discuss the rest of the June issue of the Journal, which takes a close look at issues surrounding suicide and severe depression.

• 01:20 Tucciarone and Schatzberg interview
• 03:36 Disparity between effects on suicidal ideation and antidepressant ratings
• 05:36 Ethics of placebo and ketamine in patients with suicidal ideation
• 08:28 Immediate clinical implications
• 11:40 Limitations
• 14:10 Further research
• 16:19 Kalin interview
• 16:24 Tucciarone et al.
• 20:39 Rovers et al.
• 24:30 Jelen et al.

Transcript

Board-certified psychiatrists, if you're seeking meaningful inpatient work with real clinical autonomy, consider becoming the Clinical Director for a 16-bed behavioral health hospital in Fergus Falls or Bemidji, Minnesota. You'll lead a supportive interdisciplinary team, enjoy predictable work-life balance, and have opportunities for teaching and mentorship without RVU pressure or third-party billing. Learn more on APA's Career Center, JobCentral, by searching Direct Care and Treatment – State of Minnesota.

Direct Care and Treatment – State of Minnesota: bit.ly/DCTClinicalDirector

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org